TC Medical(SH:600763)2024-07-24 12:00Investment Rating - The report does not explicitly state an investment rating for the company Core Insights - The company, Tongce Medical, known as the "Iron Rooster" for its reluctance to distribute dividends, has only distributed 190 million yuan in dividends over 18 years, with a significant market value decline of 90% [1] - In response to regulatory pressure, the company has recently increased its cash dividend payout to 140 million yuan, representing a 28% cash dividend ratio [3] - The company's revenue growth has significantly slowed, with a compound annual growth rate (CAGR) of nearly 38% from 2006 to 2021, but a decline in revenue was observed in 2022, with only a 5% growth in 2023 [6][10] - The company has faced challenges in maintaining competitiveness in the mid-to-high price market, leading to a decrease in average customer spending [12][13] - The dental market in China is highly fragmented, with the company struggling to expand outside its home province of Zhejiang, where it has historically dominated [16][19] - The company has shifted its expansion strategy from self-built facilities to acquisitions and franchising due to difficulties in replicating its success in new regions [28][30] Summary by Sections Revenue and Growth - The company experienced a revenue decline in 2022, with 2023 revenue at 2.85 billion yuan, reflecting a growth rate of only 5% [6][10] - The revenue distribution across major business segments remains stable, with implant services contributing 17.81% and orthodontics 18.56% in 2023 [9] Market Position and Competition - The company holds a mere 1.8% market share in the domestic dental service market, indicating limited competitive advantage [14][15] - The dental service market is characterized by intense competition, particularly in the low-price segment, where the company has been slow to establish a foothold [14][16] Financial Performance - The company's gross margin has declined to 38.5% in 2023, down nearly 8 percentage points from 2021, primarily due to falling customer spending [31][34] - Despite challenges, the company maintains a return on equity (ROE) above 10%, indicating reasonable profitability [42][46] Management and Governance - The company's controlling shareholder has faced regulatory scrutiny, receiving two warning letters for issues related to fund misappropriation and lack of transparency [35][36] - The management's approach to expansion and operational strategy has been criticized for lacking clarity and effectiveness, particularly in light of declining performance metrics [30][31]